Seattle Genetics, Inc. Highlights Antibody-Drug Conjugate (ADC) Program And Technology Advances At American Association for Cancer Research
Published: Apr 07, 2014
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted research related to its antibody-drug conjugate (ADC) programs and technology in more than 15 presentations at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held April 5 to 9, 2014 in San Diego, CA. The presentations describe promising advances that further enhance its ADC technology platform and review preclinical data from its proprietary SGN-CD19A and SGN-CD70A programs that support ongoing clinical development activities.
Help employers find you! Check out all the jobs and post your resume.